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A B S T R A C T
Background: The aim of this paper is to analyze the effectiveness of corticosteroid injections (CI), in
combination with or without a local anaesthetic, for Civinini–Morton’s Syndrome to determine which
protocol could be the most appropriate among conservative treatments.
Methods: All selected articles were screened using a thorough database search of PubMed, EMBASE and
SCOPUS to assess their suitability to the research focus.
Results: Selection produced 10 articles as full-text, for a total of 590 patients, with a mean follow-up of
14  14.2 (range 3–48) months. Johnson satisfaction scale, resulting from 6 studies, scored 25.6% (range
5–38) and 39.4% (range 15–51.8), respectively completely satisfied and satisfied with minor reservations.
Mean VAS, declared in 5 studies, decreased from 70.7  16.5 (range 67–89) to 33.4  7.6 (26–42.5) points
(p < 0.01). Most common complication was skin depigmentation in 7 (2.6%) cases.
Conclusions: CI appear to be a safe treatment allowing good results with a very low complications rate. A
neuroma of 6.3 mm seems to be the cut-off size; below which CI could have best indications and be
considered as an intermediate treatment between shoe modifications and more invasive procedures such
as percutaneous alcoholization or surgery.
Level of evidence: Level II, systematic review.
© 2020 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.
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Morton's neuroma is a frequent forefoot pain condition,
affecting mainly middle-aged females with a ratio female:male
5:1 [1–5]. The pathology originates from the common digital
plantar nerves and strikes mainly in the third inter-metatarsal
space (IMS), followed as incidence by the second, known as
Hauser's Neuroma [6]; localization in the first and fourth IMS is
extremely rare [7].
Civinini Morton’s Syndrome (CMS), the more correct terminol-
ogy as Pisani suggests [8], causes an important interdigital
neuropathic pain.
Surgical treatment has been considered the gold standard and it
is still widely used [9]. Other treatment managements as cryogenic
neuroablation have been also proposed [10], with a success rate
similar to surgical excision.
Among non-surgical treatments for CMS, in the last decades
satisfactory clinical results through percutaneous alcohol injection
under ultrasound guidance (USG) [11] and percutaneous electro-
stimulation-guided alcoholization with phenol [12,13] have been
reported. Nevertheless, corticosteroid injection (CI) is considered
the first-choice treatment, with better results than other
conservative treatments such as shoes modification [3] and
anaesthetic injections alone [14], this latest, often used also as
diagnostic “block” test [15]. Several studies with discordant results
with CI are reported in the literature [1,3] and different
modifications, such as the use of a corticosteroid combined with
a local anaesthetic [16] or using USG during the procedure [17], are
still debated.
No reviews assessing the effectiveness of corticosteroid
injections for CMS have been published yet in the literature;
therefore, the aim of this study was to systematically analyse the
available literature relating the evidence base of CI in patients
affected by CMS.
2. Materials and methods
The following data are the result of a thorough search of useful
literature on PubMed, Google Scholar, Embase, Medline and
Medscape. The PRISMA 2009 flow chart and checklist were
considered to revise the paper [18]. To identify studies relating to
corticosteroid injections of CMS, a clinical question was defined
using the population, intervention, comparison, outcome and
study type (PICOS) format prior to establishing the search strategy.
Population was defined as adults aged 18 years or older with a CMS
diagnosed through clinical symptoms, sonography or magnetic
resonance imaging, without a history of significant trauma, foot
surgery or systemic inflammatory conditions. Intervention was
defined as any non-surgical corticosteroid injection, with the
exclusion of alcohols and phenol, that aimed to reduce pain
associated with CMS. Authors utilized different combinations of
the following keywords: Morton, neuroma, Civinini, steroid
injection, interdigital nerve. Two authors (G.C. and A.R.) indepen-
dently examined titles and abstracts of all the identified articles to
evaluate their inherent research focus. The full-text of the selected
documents were then evaluated. References from identified
articles have been verified for do not missing any relevant items.
Inclusion criteria were: studies related to correct indications,
management and clinical outcomes of corticosteroid injections in
patients affected by CMS; retrospective or prospective clinical
studies including randomized and non-randomized controlledPlease cite this article in press as: E. Samaila, et al., Effectiveness of cor
review, Foot Ankle Surg (2020), https://doi.org/10.1016/j.fas.2020.05.001trials (RCTs), case series, cohort studies and case-control studies;
papers in English without any restriction on publication year. The
exclusion criteria were: articles that did not provide data related to
correct indications, management and clinical outcomes of
corticosteroid injections in patients affected by CMS; experimental
biomechanical or cadaveric studies; review, meta-analysis, single
case report and non-English written articles. Studies that provided
data related to injections for CMS but not specifically related to CI
were even excluded (Fig. 1).
When available, the following data were obtained from the
individual articles: first author, year of publication, study design,
number of patients (divided by groups in case of controlled
studies), average age of patients (years), type of procedure
performed, number of injections, average follow-up (FU) (months),
IMS affected, complications, need of surgery or further injections
and clinical evaluation. Studies that did not declare a specific
variable were excluded from the global assessment of that
variable; categorical data were expressed as number of cases or
percentage. Continuous variables were referred as mean and
standard deviation (SD) or mean and interval. The Level of
Evidence (LOE) of the studies was assigned based on the Evidence
Based Evidence Center of the Oxford Center for Evidence [19].
3. Results
3.1. Demographics
The selection produced a total of 10 articles regarding the
correct indications, management and clinical outcomes of
corticosteroid injections in patients affected by CMN (Table 1).
Included studies encompassed a total of 713 patients (794 feet)
and 590 among them underwent CI plus anesthetic or cortico-
steroid alone. The remaining 123 patients did not perform CI or
were used as control groups. These patients were not included in
the data analysis.
For the studies that declare it [1,3,14,16,17,20–23], 549 were
females (81.1%) and 128 were males (18.9%). Only one author [24]
describes 33 female feet and 12 male feet. The average age of
patients at time of injections was 54.5  2.4 (range 51.9–58.1)
years. The mean follow-up was 14  14.2 (range 3–48) months.
Studies took place in United States of America (1 study) [21],
Turkey (1 study) [3], United Kingdom (3 studies) [14,22,24],
Australia (2 study) [1,20], Spain (2 studies) [16,17] and Korea
(1study) [23]. The studies consisted in five randomized clinical
trials (RCTs) [3,14,16,17,24] and five case series (CS) [1,20–22].
According to the Oxford level of evidence scale [25], level of
evidence was rated as 2 in five cases and 4 in the other studies.
3.2. Interspace involved
The sites of treated neuromas were reported only in six articles
[1,3,6,16,17,21] describing 386 patients. The third IMS was affected
in 280 (72.5%) cases, the second in 84 (21.8%), while only in 27 (7%)
cases the interspaces were both treated. In 204 patients
[14,20,22,24] the IMS affected was not specified.
3.3. Diagnosis
The diagnostic protocol used was not uniform in the analysed
studies. Most authors utilized a clinical evaluation and an
instrumental confirmation before injections [1,14,16,17,22,23],ticosteroid injections in Civinini–Morton’s Syndrome: A systematic
Fig. 1. The PRISMA flow chart illustrates the number of studies examined, included and excluded, as well as the reason for the exclusion.
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The diagnostic methods were described in detail in 8 studies, for a
total of 470 patients [1,3,16,20–24]. Physical examination
findings were reported in 100% of cases, in which were evaluated
Mulder's click in 470 patients (100%), palpable pain in 426
(90.6%), IMS sensory loss in 252 (67.5%), interspace tenderness in
148 (31.5%), metatarsalgia and swelling in 44 (9.4%). Medical
history of patients was evaluated in 99 cases (21,1%) including pain
magnitude, location, intensity and restrictions of activity
[16,21,22]. Imaging tools were utilized in 7 studies, enclosing
447 patients [1,14,16,23,17,22–24]: in 431 cases (96.5%) sono-
graphic confirmation was used, while in 16 patients (3.5%)
the diagnosis was confirmed by Magnetic Resonance Imaging
(MRI). In only 39 cases (8.7%), patients were also evaluated by
conventional X-ray [22]. Two authors declare physical examination
with US confirmation [14,17], without specifying the detail of
clinical procedure.
3.4. Injection procedure
Injections of corticosteroid plus anaesthetic were compared
with footwear modifications in only 1 study [3]. Two RCT studies
compared injections of corticosteroid plus anaesthetic free-hand
performed and USG technique [17,24]. Injections of corticosteroid
plus anaesthetic were compared to anaesthetic alone injections by
two RCT’s [14,16]. The remaining five studies were case series
reporting results obtained with corticosteroid plus anaesthetic
injections [1,20–23].
Different combinations of steroid and local anaesthetic were
adopted. Association of corticosteroid and local anesthetic have
proved advantages when compared to anesthetic alone in only one
of the 2 RCT which considered these different options [14,16]. In
the remaining, the addition of anaesthetic to steroid reportedPlease cite this article in press as: E. Samaila, et al., Effectiveness of cor
review, Foot Ankle Surg (2020), https://doi.org/10.1016/j.fas.2020.05.001controversial results. Full details on drugs and dosage are reported
in Table 1.
There were other differences between protocols employed by
authors. In 5 studies [1,14,21,23,24] only 1 injection was
performed, except for one study in which authors performed up
to 3 injections in patients with persistent pain [23]. Three
injections were performed in 3 studies [3,16,27]. Greenfield states
one up to more than four, with a mean of 3.07 injections in all
patients, without specifying how many of them received in detail
the injections [20]. Ruiz [20] declared an average number of
injections of 2,4  0,2. One study did not specify the protocol
performed [23]. The total average of injections, for the studies that
declare it [1,3,14,16,17,20,21,24], was 1,5  0,8.
The injection technique was not uniform in the analysed
studies. Free-hand technique was used by 3 authors [3,20,21]
while USG injection was utilized in most cases [1,14,22,23]. No
differences can be found at FU between free-hand and USG
techniques [17,24]. In 2 studies [17,24] both techniques were
performed but the different techniques were not compared. For the
remainder [16], the utilized technique was not reported.
The injection approach was narrowly described in 7 studies
[1,14,17,20,21,23,24]. Authors reported a dorsal approach in most
cases [17,20,21,23,24], one author performed CI by a plantar
approach [14], while another author describes distal to proximal
injections [1].
3.5. Size of neuromas
The size of neuromas, intended as transverse diameter, was
described in 6 studies [1,14,16,17,23,24], for a total of 408 cases.
Authors reported an average size of 7.5  0.7 mm. One author
considered indicated CI inpatients with neuromas sized more than 5
mm [14]. No lesion size was declared in the other studies [3,20–22].ticosteroid injections in Civinini–Morton’s Syndrome: A systematic
Table 1
Themain features of the included studies are summarized. AOFAS: American Orthopaedic Foot &Ankle Score; FHT: Foot Health Thermometer; LOE: level of evidence;MFPDS:Manchester Foot Pain andDisability Schedule;MFPDS pr:
Manchester Foot Pain and Disability Schedule pain related; MFPDSwd: Manchester Foot Pain and Disability Schedule walking/doing; MFPDSwa: Manchester Foot Pain and Disability Schedule work/activities; MOxFQ-Index:


































































24 Not specified Self-reported relief pain:
 relieved pain in 35/59
(59,3%)
 partial relief in 17/59 (28,8%)





























1 48 (24–72) None Johnson satisfation scale:
 completely satisfied 19/50
(38%)
 satisfied minor reservations
9/50 (18%)
 satisfied major reservations
10/50 (20%)
 dissatisfied 12/50 (24%);
Mann scale, 26/50 (52%):
 reported less than 50% im-
provement














































2 12 Not specified Self-reported satisfaction:
 82% completely satisfied

































11.4 None Self-reported relief pain:
 28% complete pain relief
 26% mild pain
 28% moderate pain
 18% severe pain;
Johnson satisfaction scale:
 31% completely satisfied
 15% satisfied with minor
reservetions

























































































































1 9 None Lower extremity functional
scale:
 28% complete pain relief
 44% mild pain (at 1 month)
 31% non responder to con-
servative treatment;
Johnson satisfaction scale:
 38% completely satisfied
 28% satisfied with minor
reservetions






























acetate (40 mg) +1
mL 2% Lignocaine
or






1 12 5% skin
depigmentation (or
atrophy of the plantar
fat pad) in Group 1
FHT:
 Group 1: 64.7  22
 Group 2: 50.9  27.2;
VAS: Group 1: 44.5  23.3
 Group 2: 51.5  24.6;
MFPDSpr: Grou 1: 35.5  23.5
 Group 2: 39.8  23.2;
MFPDSwd: Group 1 30.5  21.5
 Group 2: 41.9  26.3;
MFPDSwa: Group 1: 18.9  23.1
























































1 12 4.5% skin
depigmentation in
Group 2
VAS, MOxFQ-Index were not
statistically significant at all
time-points;
Johnson satisfaction scale at 3
months:
Group 1:
 completely satisfied 30.5%
 satisfied with minor reser-
vation 39%
 satisfied with major reser-
vation 4.5%
 dissatisfied 26%;
Group 2: completely satisfied 5%
 satisfied with minor reser-
vation 45%
 satisfied with major reserva-
tion 23%
 dissatisfied 27%;
Johnson satisfaction scale at 12









































Group 2: 2 mL
3 6 Not specified VAS, AOFAS and Johnson
satisfaction scale scores





















































































































































 37.5% completely satisfied
 25% satisfied with minor
reservetions
 19% satisfied with major
reservetions
 18.5% dissatisfied;
Group 2: 32% completely satisfied
 26% satisfied with minor
reservetions





















































6 Not specified VAS: 2.6 (8.9 at start)
Johnson satisfaction scale:
 20.4% completely satisfied
 51.8% satisfied with minor
reservetions



























































 5/27 (18,5% skin de-
pigmentation);
Group 2: 1/27 (3.7% skin de-
pigmentation)
 1/27 (3.7% local
hypersensitivity)
 1/27 (3.7% crossover
toe)
VAS and MFPDS showed
no significative differences at 6
months;
Group 2 proved better results



























































































Level of Johnson Satisfaction Scale (JSS) after treatment (386 patients).
Completely satisfied Satisfied minor reservations Satisfied major reservations Dissatisfied
Patient (n/tot) 99/386 152/386 56/386 79/386
Percentage % (range) 25.6% (5–38) 39.4% (15–51.8) 14.5% (10–19) 20.5% (14.9–41)
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Clinical evaluation at FU was described in all the studies
[1,3,14,16,17,20–24]. Different combinations of functional evalua-
tion scales were used. Authors declared: Johnson Satisfaction Scale
(JSS) in 386 (65.4%), Visual Analogue Scale (VAS) in 373 (63.2%)
patients, Manchester Foot Pain and Disability Schedule (MFPDS) in
120 (20.3%), Self-reported relief pain in 98 (16.6%), Lower
extremity functional scale in 35 (5.9%), Self-reported Satisfaction
(SRS) in 34 (5.8%), Foot Health Thermometer (FHT) in 64 (10.8%),
Mann scale in 44 (7.5%), Manchester-Oxford Foot Questionnaire
(MOxFQ) Index in 36 (6.1%) and American Orthopaedic Foot &
Ankle Score (AOFAS) in 16 (2.7%).
JSS, used in most studies [1,16,21–24], showed 25.6% (range 5–
38) and 39.4% (range 15–51.8) of patients respectively completely
satisfied and satisfied with minor reservations. Details of JSS are
reported in Table 2.
VAS scores were declared only in 5 studies [14,16,17,23,24]; pre-
and post CI scores were compared using T-Student test. A p < 0.01
was considered statistically significant. Mean VAS decreased from
70.7  16.5 (range 67–89) to 33.4  7.6 (26–42.5) points (p < 0.01).
Full details of clinical outcomes with all the considered evaluation
scores are reported in Table 1.
3.7. Complications
Complications were reported in 6 studies [1,14,17,21,22,24],
including 264 patients: skin depigmentation in 7 cases (2.6%), local
hypersensitivity and crossover toe in 1 (0.4%). Thomson [14]
observed a skin depigmentation or atrophy of the plantar fat pad in
5 patients (1.9%), without specifying which of them had one or
both adverse effects. For the remainders [3,20,16,23] complication
findings were unknown.
3.8. Further interventions
In 8 studies, for a total of 588 patients, further procedures were
required in 139 cases (23.6%) [1,14,16,20–24]: excision surgery in
130 cases (22.1%), further CI, in addition to own protocol, in 9
(1.5%). For two authors [3,17] no other interventions were required.
4. Discussion
CMS is not really a neuroma, but a perineural fibrosis with
vascular proliferation and intraneural sclerohyalinosis of the
common digital nerve, causing an important interdigital neuro-
pathic pain [26]. Therefore, some authors, as Weinfield and
Myerson, proposed the more correct term of “interdigital neuritis”
[27].
The condition was first recognized as a specific anatomical-
entity by the Italian anatomist Filippo Civinini in 1835 [28], during
a cadaveric dissection, and clearly described in his anatomic letter
entitled “On the neural gangliar swelling of the foot sole".
Subsequently, the English surgeon Lewis Durlacher in 1845 [26]
described it as "a form of neuralgic condition affecting the plantar
nerve between the third and fourth metatarsal bone". This last
description better respects current pathogenic concepts. Finally, in
1876 the American surgeon Thomas G. Morton [4] wronglyPlease cite this article in press as: E. Samaila, et al., Effectiveness of cor
review, Foot Ankle Surg (2020), https://doi.org/10.1016/j.fas.2020.05.001attributed the symptoms to subluxation of the fourth metatarso-
phalangeal (MTP) joint, proposing its excision. Thus, even if the
term came commonly into use in the 19th century, the attribution
to Morton is not correct from a pathological point of view. For these
reasons, since the designation to Morton is widely used, the more
correct terminology should be “Civinini–Morton Syndrome” [8].
The common plantar digital nerves are final branches of the
medial and lateral plantar nerves passing from the plantar
webspace beneath the intermetatarsal ligaments. Each common
digital nerve run within the plantar aponeurosis and splits into 2
branches providing the plantar skin of the toes. Smaller
ramifications provide innervation to the adjacent metatarsals,
MTP joints, and plantar skin under the metatarsal heads [29].
Ordinarily, the third common digital nerve, deriving from the
medial plantar nerve, receives a communicating bough from the
lateral plantar nerve, which passes deep to the transverse
metatarsal ligament at the third IMS, which is the narrowest
space, and being for this reason less mobile during weightbearing,
it is explained why this is a common location for the syndrome
[30]. Women are usually affected much more than men, lending
credence to the presupposition that footwear is a contributing
factor in the aetiology of this disorder [4].
Nowadays, four etiopathogenetic theories have been proposed
[31]: chronic traction damage [30], inflammatory environment due
to intermetatarsal bursitis [32], compression by the deep
transverse intermetatarsal ligament [33] and ischemia of vasa
nervorum [34].
Nevertheless, some of these biomechanical convictions have
been denied over the years. The belief that CMS would more
commonly occur in the third interspace in a more pronated foot,
because of hypermobility of the lateral column relative to the
medial column, is not supported anymore from the recent studies.
Even the reasonable hypothesis that individuals with a high body
mass index (BMI) should increase pressure in the forefoot during
the propulsive phase of gait, which could traumatize plantar
interspace nerves, was not confirmed by latest gait analysis
outcomes. However, a strong association between the presence of
CMS and a restriction of ankle dorsiflexion was demonstrated [35].
CMS diagnosis is mostly clinical and needs an accurate physical
examination through various signs described in literature. Thumb
index finger squeeze test and Mulder’s sign appear to have the
highest sensibility and sensitivity [30,36]. In the analysed studies,
Mulder’s click has been evaluated in 100% of cases, together with
palpable pain (90.6%) and IMS sensory loss (67.5%). Sonographic
confirmation has been the mostly used [1,14,16,27,22–24] and
latest studies appears to confirm its utility, having even equal
sensitivity of MRI for identification of neuroma and its size [37].
However, a negative result does not exclude the diagnosis (false
negative 17%) [38].
Conservative measures such as manipulation, footwear modi-
fication, padding and injective treatments are the first therapeutic
approach for the treatment of the disease and many studies
evaluating their results can be found in literature [2,3,4,39].
Among these, the less invasive ones (manipulation, footwear
modification and padding) are appreciated by patients but, despite
of their usefulness, they cannot guarantee better results than
injective treatments. Better outcomes with manipulations were
reported by Govender in his RCT study [40], compared to patientsticosteroid injections in Civinini–Morton’s Syndrome: A systematic
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FAS 1455 No. of Pages 9treated with placebo. Metatarsal pad, usually molded on patient’s
foot, or shoes modifications showed successful effects in 32% of
cases [3,4,41].
Among injections treatments, corticosteroid with or without
anaesthetic is widespread utilised but even alcohol sclerosing and
botulinum toxin have been used. The first is widely studied and a
reduction of pain can be expected in 68–80% of cases [5,13,41–43],
while the second was reported in a pilot study involving only 17
patients and showed to be of possible usefulness, opening the door
to further clinical researches [39].
CI provides better results compared to shoes modification alone
in 82% of patients which referred to be completely satisfied at 12
months [3]. On contrary, unsatisfactory results with CI were
reported in 2 different case series [1,22], in which a complete pain
relief was obtained respectively in 28% and 46% of patients. Despite
these fickle results, injections may reduce significantly VAS score
and improve patients’ feet function [14].
This systematic review, for our knowledge, is the only one
existing in the literature evaluating the reliability of CI associated
or not to anesthetic. Thomson [14] favoured steroid plus
anaesthetic reporting an improvement of a mean 14.1 points
using the Foot Health Thermometer (FHT) scale and a significant
improvement in Manchester Foot Pain and Disability Schedule
walking/doing (MFPDSwd) at 3 months follow-up compared to the
anaesthetic injection alone. Differently, Lizano-Diez et al. [16]
stated that VAS, AOFAS and JSS do not significantly differ in
patients treated with corticosteroids with or without anesthetic. A
meta-analysis of these two trials [14,16] was also performed by
Matthews et al. [41], affirming that the drugs combination
(corticosteroid plus anaesthetic injection) seems to be more
effective than anaesthetic injection alone (Weighted Mean
Difference: 5.3, 95% CI: 7.5 to  3.2). Continuous outcome
measures for four of the here considered studies [17,19,26,27]
showed a pre/post reduction in pain at a mean of 6.8 months (range
3 to 12) (WMD: 34.6, 95% CI: 58.1 to 11.2) [41].
Concerning the injection procedure, no differences were found
at FU between free-hand and USG techniques [17,24], and no study
compared different approaches.
About protocol adopted, studies reporting good results range
from 1 to 3 injections but, despite this, Jain [30] suggested that 3
injections should be performed and Thomas [36] reported that
multiple injection would obtain better results. However, a recent
systematic review and meta-analysis on all conservative treat-
ments [41] found that there is no evidence of better results
obtained with several injections instead of a single shot and binary
outcome measures with six studies [1,3,19,25–27] demonstrated
success following CI at a mean of 8.4 months (range 6–12) (WSR:
34, 95% CI: 21–49%).
Free-hand or USG technique were described [3,44]: both are
safe even if free-hand injection appears to give more skin
complications than the USG procedure [17].
Among studies we evaluated, only 2 reported comparative
results of the two techniques [2,24] and with these data no
significant differences can be found between them. Approaches to
the foot have been recorded from distal to proximal [1], plantar
[14] and dorsal [17,20,21,23,24], but it was not possible to compare
the results to indicate the best approach.
Moreover, neuroma’s size could be hypothesized as a relevant
factor for treatment success. Mahadevan et al. [24] asserted that
neuromas with transverse diameter of more than 5 mm had worse
results and Park et al. [23] declared that a big size neuroma is an
important risk factor for the need of further treatments with a
recurrence rate of 84% in patients with neuromas sized more than
6.3 mm.
CI are burdened by complications such as skin depigmentation
and plantar fat pad atrophy [14,16,24]. Skin depigmentation wasPlease cite this article in press as: E. Samaila, et al., Effectiveness of cor
review, Foot Ankle Surg (2020), https://doi.org/10.1016/j.fas.2020.05.001the most common complication, with a rate ranging from 5% to 18%
of cases [14,17,24].
Latest studies [45] confirmed as CI remains the mainstay of
conservative treatment with excellent or good satisfaction overall,
and could be considered a safe intermediate treatment between
simple shoe modifications and more invasive interventions.
Indeed, in case of unsatisfactory results, procedures such as
percutaneous alcoholization or operative options, including nerve
decompression, cryogenic neuroablation or neurectomy, can
always be performed.
This review has several limits. First, there is an inhomogeneity
regarding the type of studies which are reported in literature on
this topic and consequently a risk-of-bias assessment. The analysis
is mainly based on II-IV LOE studies, the samples are non-
homogenous, data are often incomplete and the follow-up is
mainly at short- to mid-term. Despite this, the review could
provide useful information on correct indications, management,
clinical outcomes and expectations of CI in patients affected by
CMS, setting the basis for further high-quality studies about this
frequent foot pain condition.
5. Conclusion
This literature review analyses results in terms of pain reduction
and patient satisfaction after CMS injective steroid treatment.
Sonographic diagnosis is useful for instrumental confirmation,
particularly to identify large neuromas. With the available data, no
substantial differences were found with injections performed
through dorsal, plantar or distal to proximal approaches. No
difference was found using free-hand or USG techniques, although
the free-hand technique seems to give more skin complications
Despite this, CI may be considered a safe intermediate
treatment between shoe modifications and more invasive inter-
ventions.
Notwithstanding a good quality of the selected articles, further
studies with a longer follow-up period and high quality RCTs are
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